NO20075721L - New crystalline atorvastatin hemicalcium salt polymorph form - Google Patents

New crystalline atorvastatin hemicalcium salt polymorph form

Info

Publication number
NO20075721L
NO20075721L NO20075721A NO20075721A NO20075721L NO 20075721 L NO20075721 L NO 20075721L NO 20075721 A NO20075721 A NO 20075721A NO 20075721 A NO20075721 A NO 20075721A NO 20075721 L NO20075721 L NO 20075721L
Authority
NO
Norway
Prior art keywords
polymorph form
atorvastatin hemicalcium
hemicalcium salt
new crystalline
crystalline atorvastatin
Prior art date
Application number
NO20075721A
Other languages
English (en)
Norwegian (no)
Inventor
Peter Kotay Nagy
Gyula Simig
Kalman Nagy
Jozsef Barkoczy
Zsuzsanna Szent-Kirallyi
Ferenc Bartha
Zoltan Katona
Gyorgyi Vereczkeyne Donath
Norbert Nemeth
Gyorgy Ruzsics
Original Assignee
Egis Gyogyszergyar Nyilvanosan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0500370A external-priority patent/HU0500370D0/hu
Priority claimed from HU0600120A external-priority patent/HUP0600120A3/hu
Application filed by Egis Gyogyszergyar Nyilvanosan filed Critical Egis Gyogyszergyar Nyilvanosan
Publication of NO20075721L publication Critical patent/NO20075721L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20075721A 2005-04-08 2007-11-08 New crystalline atorvastatin hemicalcium salt polymorph form NO20075721L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0500370A HU0500370D0 (en) 2005-04-08 2005-04-08 New crystalline atorvastatin hemicalcium polimorph
HU0600120A HUP0600120A3 (en) 2006-02-14 2006-02-14 New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it
PCT/HU2006/000026 WO2006106372A1 (en) 2005-04-08 2006-04-07 New crystalline atorvastatin hemicalcium salt polymorph form

Publications (1)

Publication Number Publication Date
NO20075721L true NO20075721L (no) 2008-01-04

Family

ID=89986585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075721A NO20075721L (no) 2005-04-08 2007-11-08 New crystalline atorvastatin hemicalcium salt polymorph form

Country Status (12)

Country Link
US (1) US20090215855A1 (cs)
EP (1) EP1868993B1 (cs)
JP (1) JP5523699B2 (cs)
BG (1) BG66035B1 (cs)
CZ (1) CZ2007772A3 (cs)
EA (1) EA014079B1 (cs)
IL (1) IL186499A (cs)
NO (1) NO20075721L (cs)
RO (1) RO200700700A8 (cs)
RU (1) RU2409563C2 (cs)
SK (1) SK288276B6 (cs)
WO (1) WO2006106372A1 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080007561A (ko) 2005-12-13 2008-01-22 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
US20090240064A1 (en) * 2006-02-22 2009-09-24 Venkata Panakala Rao Gogulapati Crystalline form of atorvastatin hemi-calcium
US20120244220A1 (en) * 2009-12-25 2012-09-27 Sawai Pharmaceutical Co., Ltd. Atrovastatin-containing coated preparation
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
KR100431038B1 (ko) * 1995-07-17 2004-05-12 워너-램버트 캄파니 엘엘씨 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴)
KR100704213B1 (ko) * 2000-11-03 2007-04-10 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 ｖｉｉ형
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
NZ527048A (en) * 2000-12-27 2004-12-24 Ciba Sc Holding Ag Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
KR100724515B1 (ko) * 2002-02-15 2007-06-04 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미칼슘의 신규한 결정형, 이의 제조 방법 및 아토르바스타틴 헤미칼슘 i형, viii형 및 ix형을 제조하는 신규한 방법
JP4422488B2 (ja) * 2002-02-19 2010-02-24 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム

Also Published As

Publication number Publication date
BG66035B1 (bg) 2010-11-30
US20090215855A1 (en) 2009-08-27
IL186499A (en) 2016-04-21
SK51252007A3 (sk) 2008-07-07
SK288276B6 (sk) 2015-06-02
EP1868993B1 (en) 2014-04-30
IL186499A0 (en) 2008-01-20
RO123642B1 (ro) 2015-07-30
EA014079B1 (ru) 2010-08-30
EA200702191A1 (ru) 2008-04-28
EP1868993A1 (en) 2007-12-26
RU2409563C2 (ru) 2011-01-20
JP2008534669A (ja) 2008-08-28
BG109992A (bg) 2008-05-30
WO2006106372A1 (en) 2006-10-12
CZ2007772A3 (cs) 2008-02-27
RU2007140797A (ru) 2009-05-20
WO2006106372A8 (en) 2008-03-13
JP5523699B2 (ja) 2014-06-18
HK1117141A1 (en) 2009-01-09
RO200700700A8 (ro) 2015-07-30

Similar Documents

Publication Publication Date Title
GEP20053546B (en) Crystalline Forms of 'R-(R*,R*)!-2-(4- Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-'Phenylamino) Carbonyl!-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) (Atorvastatin)
YU56803A (sh) Pripremanje nekristalinskog atorvastatin-kalcijuma
DE60239425D1 (de) Kalziumatorvastatin enthaltende arzneiformulierung
AR003458A1 (es) Forma cristalina de atorvastatina o hidrato de la misma y composicion farmaceutica que la comprende.
EE9800016A (et) Vorm III kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hepta anhappe hemikaltsiumsool (atorvastatiin)
NO20075721L (no) New crystalline atorvastatin hemicalcium salt polymorph form
EE200200293A (et) Meetod amorfse atorvastatiini valmistamiseks
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
MXPA04000889A (es) Formas cristalinas vi y vii de atorvastatina calcica.
NO20060446L (no) Trisykliske delta-opioidmodulatorer
CA2406266A1 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
DK0669912T3 (da) N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
CA2508871A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
MA29950B1 (fr) Nouveau derive de la pleuromutiline et son utilisation
WO2009007856A3 (en) Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
DE69930621D1 (de) Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
UA93202C2 (ru) Полиморфная форма кристаллической гемикальциевой соли аторвастатина
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
KR20080070951A (ko) 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
TW200738624A (en) Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
AR045654A1 (es) Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoico
RU2006136361A (ru) Терапевтическая комбинация для лечения болезни альцгеймера
EP2117516A2 (en) Stable atorvastatin formulations
IS7019A (is) Kristallaform af 'R-(R*,R*)!-2-(4-flúorfenýl)-beta, delta-díhýdroxý-5-(1-metýletýl)-3-fenýl-4-'fenýlamínó)karbónýl!-1H-pýrról-1-heptansýru kalsíum salt (2:1) (atorvastatín)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application